ADMA
$14.32-0.70 (-4.66%)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Recent News
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
FDA Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients
NVO wins FDA's accelerated nod for a higher 7.2 mg Wegovy dose, backed by strong phase III weight-loss data, with a U.S. launch planned for April 2026.
Adma Biologics (ADMA) Advances While Market Declines: Some Information for Investors
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $15.02, denoting a +1.01% move from the preceding trading day.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?